Safety and efficacy of rabies immunoglobulin in pediatric patients with suspected exposure
Saturday, October 3, 2020
11:00 AM – 11:25 AM CDT
Please join us for a presentation by Dr. Nicholas Hobart, DO on: Safety, tolerability, and efficacy results of a phase 4 clinical trial examining use of a rabies immunoglobulin as part of post-exposure prophylaxis in pediatrics. Following suspected rabies virus exposure, prophylaxis with rabies immunoglobulin and vaccine is indicated to prevent rabies in unvaccinated persons. Pediatric patients bear a significant disease burden, but no pediatric safety or efficacy data exist for any current rabies immunoglobulins. This study investigated the safety and efficacy of a rabies immunoglobulin (HRIG150; KEDRAB™) when used as part of PEP in pediatric patients. No serious adverse events or rabies infections were observed, and all adverse events were mild in severity.